• A-769662: Precision AMPK Activator for Metabolic Research

  2026-04-30

  A-769662, a potent and reversible AMPK activator, offers researchers an advanced toolkit for dissecting cellular energy regulation, fatty acid synthesis inhibition, and proteasome function. Its well-characterized mechanism and robust selectivity make it indispensable for metabolic syndrome and type 2 diabetes studies, while new mechanistic insights redefine its role in autophagy workflows.

• IMPDH Inhibition Impairs PEDV Replication via Nucleotide Met

  2026-04-30

  This study demonstrates that porcine epidemic diarrhea virus (PEDV) critically depends on host guanine nucleotide biosynthesis, specifically targeting inosine monophosphate dehydrogenase (IMPDH). Both genetic and pharmacological inhibition of IMPDH, including with Merimepodib (VX-497), robustly suppress PEDV replication, establishing IMPDH as a promising host-directed antiviral target for veterinary virology.

• Trelagliptin Promotes Osteoblast Differentiation via RUNX2 a

  2026-04-29

  This study demonstrates that Trelagliptin, a DPP-4 inhibitor, enhances osteoblastic differentiation by upregulating RUNX2 and activating AMPK signaling in MC3T3-E1 cells. These findings suggest a novel therapeutic potential for Trelagliptin in osteoporosis management and provide mechanistic insights relevant for bone biology research.

• PDHA1 Acetylation Suppresses Cuproptosis in Prostate Cancer

  2026-04-29

  This study uncovers a novel mechanism of castration-resistant prostate cancer (CRPC) resistance to anti-androgen therapy, where PDHA1-mediated acetylation suppresses cuproptosis and reduces enzalutamide efficacy. Targeting PDHA1 restores cuproptosis and sensitizes CRPC cells, suggesting new avenues for overcoming therapeutic resistance.

• Structural Insights into Human Organellar SPFH Protein Compl

  2026-04-28

  This study elucidates the architectures of human organellar SPFH complexes, specifically Erlin1/2 in the ER and PHB1/2 in mitochondria, using single-particle cryo-EM. The findings reveal distinct stoichiometries and assembly principles, advancing our understanding of SPFH-mediated membrane organization and protein quality control.

• JNJ-26854165 (Serdemetan): Elevating Translational Cancer Re

  2026-04-28

  This thought-leadership article dissects the mechanistic, experimental, and translational value of JNJ-26854165 (Serdemetan) as a small molecule HDM2 antagonist, offering actionable guidance for academic and industry researchers pursuing innovative cancer biology. Drawing from recent in vitro methodological advances and strategic best practices, it frames Serdemetan as a catalyst for robust, reproducible, and clinically relevant p53 pathway modulation.

• Talin1–Piezo1–YAP Axis: Calcium Signaling in Endothelial Inf

  2026-04-27

  This study identifies Talin1 as a critical modulator of the Piezo1–YAP signaling axis in endothelial cells, directly linking mechanical and inflammatory stimuli to atherosclerotic progression. By elucidating how calcium influx via Piezo1 activates Talin1 and drives inflammation, the research highlights potential targets for anti-inflammatory intervention in vascular disease.

• Ruxolitinib Phosphate Induces Apoptosis in Anaplastic Thyroi

  2026-04-27

  This study demonstrates that Ruxolitinib phosphate (INCB018424) induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) by targeting the JAK1/2-STAT3 pathway and transcriptionally inhibiting DRP1-mediated mitochondrial fission. The findings reveal a novel mechanistic link between JAK/STAT signaling and mitochondrial dynamics, suggesting new approaches for aggressive thyroid cancer research.

• Tivozanib (AV-951): Applied Workflows for VEGFR Inhibition

  2026-04-26

  Tivozanib (AV-951) delivers benchmark selectivity and potency in anti-angiogenic research, enabling precise dissection of VEGFR signaling in oncology models. This guide translates advanced in vitro methodology and troubleshooting strategies into actionable, reproducible protocols for cancer researchers.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-04-25

  Cy5 NHS ester(Et) is a water-soluble, amine-reactive fluorescent dye optimized for covalent labeling of primary amines in biomolecules. It addresses challenges in protein fluorescent labeling for immunofluorescence, flow cytometry, and microscopy workflows, but is not suitable for ethanol-based protocols or long-term storage of dissolved solutions.

• Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl

  2026-04-24

  Degarelix acetate enables rapid, selective GnRH receptor antagonism for advanced hormone pathway research and prostate cancer modeling. This guide details cutting-edge protocol enhancements, troubleshooting, and direct clinical insights from recent landmark studies.

• Mechanistic Insights into Diuron-Induced Acute Renal Injury

  2026-04-24

  This study integrates network toxicology, transcriptomics, and in vitro validation to elucidate how Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) induces acute kidney injury via the JAK2/STAT1 pathway. These findings advance understanding of the nephrotoxic risks posed by environmental exposure to this persistent photosynthesis inhibitor and inform future toxicological assessments.

• Defining EndoMT Molecular Signatures Across Vascular Beds

  2026-04-23

  This study delivers the first comprehensive transcriptomic atlas of endothelial-to-mesenchymal transition (EndoMT) in human vascular endothelial cells, highlighting cell-type-specific gene expression changes and identifying acetate as a potent EndoMT inhibitor. These findings provide a molecular resource for dissecting EndoMT in disease and guide future strategies for targeted therapeutic development.

• Calpain Inhibitor I, ALLN: Experimental Use and Best Practic

  2026-04-23

  Calpain Inhibitor I, ALLN is designed for the selective inhibition of calpain and cathepsin proteases in apoptosis and inflammation research models. It addresses the need for high-specificity modulation of proteolytic pathways, but should not be used for diagnostic or therapeutic purposes. Its application is best suited to controlled experimental workflows where precise inhibition and minimal off-target effects are priorities.

• Perospirone (SM-9018): Bridging Neuropsychiatric and Vascula

  2026-04-22

  Explore how Perospirone (SM-9018 free base) uniquely informs both neuropsychiatric and vascular research by integrating receptor pharmacology with direct Kv1.5 channel inhibition. Discover new experimental considerations and cross-domain assay strategies only in this in-depth analysis.

14921 records 1/995 page Next 12345 下5页 Last page